Authors

Latest:

Dr. Lara on the FDA Approval of Adjuvant Sunitinib in RCC

Primo N. Lara Jr, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the FDA approval of adjuvant sunitinib (Sutent) for high-risk patients with renal cell carcinoma (RCC).

Primo N. Lara, MD

Latest:

Dr. Lara on the Role of Sunitinib for Renal Cell Carcinoma

Primo N. Lara, MD, associate director for translational research, UC Davis Comprehensive Cancer Center, discusses the role of sunitinib (Sutent) for patients with renal cell carcinoma (RCC).

Prithviraj Bose, MD

Latest:

Highlights in MPNs, CLL With Drs Prithviraj Bose and Javier Pinilla Ibarz

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, and Javier Pinilla Ibarz, MD, PhD, of Moffitt Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest in myeloproliferative neoplasms and chronic lymphocytic leukemia, respectively, from the 2024 ASH Annual Meeting.

Priya Bhosale, MD

Latest:

Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer

An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.

Priya U. Kumthekar, MD

Latest:

Dr Kumthekar on CSF Tumor Detection in Breast Cancer or NSCLC with Leptomeningeal Disease

Priya U. Kumthekar, MD, discusses the use of a novel diagnostic platform to detect CSF tumor cells in patients with leptomeningeal disease.

Priyanka Gopal, MD

Latest:

Cleveland Clinic Researchers Explore Genetic Landscape of Radiotherapeutic Resistance

Priyanka Gopal, MD, and Mohamed E. Abazeed, MD, PhD, discuss radiotherapy in the era of precision medicine.

Priyanka Sharma, MD, University of Kansas Cancer Center

Latest:

Dr. Sharma on Optimal Systemic Therapy for Early-Stage TNBC

Priyanka Sharma, MD, discusses updates in optimal systemic therapy strategies in early-stage triple-negative breast cancer.

Prof. Bernard Escudier, MD, Institute Gustave Roussy

Prudence Francis

Latest:

Dr. Francis on the Benefits of Ovarian Suppression for Younger Women

Prudence Francis, MD

Latest:

Dr. Francis on Ovarian Suppression in Young Women With Breast Cancer

Prudence Francis, MD, Peter MacCallum Cancer Centre, discusses ovarian suppression in young women with hormone receptor (HR)-positive breast cancer.

Przemyslaw W. Twardowski, MD

Latest:

Dr. Twardowski on Steps Toward Optimal Sequencing for mCRPC Therapies

Przemyslaw W. Twardowski, MD, director, Prostate Oncology Strategic Program, director, Genitourinary Program, clinical professor, Department of Medical Oncology and Therapeutics Research, discusses the necessary steps toward determining optimal sequencing of treatments for patients with metastatic castration-resistant prostate cancer.

Public Health

Puneeth Iyengar, MD

Latest:

Dr. Iyengar on the Rationale Behind Hypofractionated Radiation in NSCLC

Puneeth Iyengar, MD, radiation oncologist, University of Texas Southwestern Medical Center, discusses the rationale behind the use of hypofractionated radiation as a treatment for patients with non–small cell lung cancer.

Qiang John Li, MD, PhD

Latest:

Robot-Assisted Cystectomy Is Feasible for Many Patients With Bladder Cancer

To determine the 10-year oncologic outcomes and recurrence patterns after robot-assisted radical cystectomy, a group within the Department of Urology at Roswell Park Comprehensive Cancer Center performed a retrospective review.

Qinyu Chen, MHS

Latest:

Radiotherapy in the Modern Era in the Management of Langerhans Cell Histiocytosis

Intensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.

Quincy Chu, MD

Latest:

Dr. Chu Discusses CNS Penetration of Ceritinib

Quincy Chu, MD, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, discusses the ability of ceritinib to penetrate the CNS.

R. Kate Kelley

Latest:

Dr. Kelley on Newly Approved Agents in HCC

R. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the clinical impact of REFLECT and CELESTIAL in hepatocellular carcinoma (HCC).

R. Kate Kelley, MD

Latest:

Dr Kelley on the Need for Additional Second-line Therapies in Cholangiocarcinoma

R. Kate (Katie) Kelley, MD, discusses unmet needs and treatment challenges within the current standard-of-care for patients with cholangiocarcinoma.

R. Kate Kelley, MD, UCSF Helen Diller Family Comprehensive Cancer Center

Latest:

Perspectives on Treating CCA Moving Forward

A panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.

R. Kate Kelley, MD, University of California-San Francisco

Latest:

Cholangiocarcinoma: Potential Therapies Under Investigation

An overview of various treatment opportunities under study that are looking at using novel techniques to help personalize treatment for patients with bile duct cancers.